Trial · NCT02170662
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
NCT02170662, Phase 2, Completed, Duke University; results first posted 2014-08-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Bimatoprost Effect on Androgen Dependent Hair Follicles. Trials, record NCT02170662. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02170662
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
- NCT number
- NCT02170662
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 33 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Male Pattern Hair Loss, Androgenetic Alopecia
- Interventions
- Bimatoprost, Placebo
- First posted
- 2014-06-23
- Last updated
- 2014-09-05
- Results first posted
- 2014-08-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Target Area Total Hair Count | Baseline to week 17; and week 17 to week 34 | The primary endpoint is the percent change in total hair count from the beginning and end of each part of the study. |
| Secondary | Percent Change in the Target Area Terminal Hair Count | Baseline to week 17; and week 17 to week 34 | Terminal hairs are those which grow beyond a cm and contribute to overall hair density. |
| Secondary | Percent Change in the Target Area Vellus Hair Count | Baseline to week 17; and week 17 to week 34 | Vellus hairs are fine hairs that generally do not grow beyond 1 cm and do not contribute to overall hair density. For the most part, they have a diameter of \<40 um. They are increased in number in male pattern baldness |
| Secondary | Percent Change in Hair Diameter | Baseline to week 17; Week 17 to week 34 | The percent change in hair diameter is a recent addition to the methods of assessing efficacy of hair growth promoters. It is a measure of hair mass and does not separate out the effect on terminal and vellus hairs but rather combines the effect on both. Since it is only terminal hairs that contributes to normal hair density, this measure does not add anything to the measures of total, terminal and vellus hair counts in terms of overall effect on hair growth and is therefore not analyzed or reported here. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Target Area Total Hair Count | Baseline to week 17; and week 17 to week 34 | intention to treat (ITT) | percentage change in total hair count | MEAN |
| SECONDARY | Percent Change in the Target Area Terminal Hair Count | Baseline to week 17; and week 17 to week 34 | percent change of terminal hair count | MEAN | |
| SECONDARY | Percent Change in the Target Area Vellus Hair Count | Baseline to week 17; and week 17 to week 34 | Percent change of vellus hair count | MEAN | |
| SECONDARY | Percent Change in Hair Diameter | Baseline to week 17; Week 17 to week 34 | Data not analyzed, and therefore not reported. |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Target Area Total Hair Count | Placebo Then Bimatoprost | Part 1: Baseline to week 17 | -2.6 | Full Range -10.4 to 2.7 | percentage change in total hair count |
| Percent Change in Target Area Total Hair Count | Bimatoprost Then Placebo | Part 1: Baseline to week 17 | 27.4 | Full Range -19.8 to 112.5 | percentage change in total hair count |
| Percent Change in Target Area Total Hair Count | Placebo Then Bimatoprost | Part 2: week 17 to week 34 | 4.9 | Full Range -2.4 to 12.0 | percentage change in total hair count |
| Percent Change in Target Area Total Hair Count | Bimatoprost Then Placebo | Part 2: week 17 to week 34 | -5.8 | Full Range -33.3 to 10.4 | percentage change in total hair count |
| Percent Change in the Target Area Terminal Hair Count | Placebo Then Bimatoprost | Part 1: Baseline to week 17 | -2.1 | Full Range -9.8 to 10.1 | percent change of terminal hair count |
| Percent Change in the Target Area Terminal Hair Count | Bimatoprost Then Placebo | Part 1: Baseline to week 17 | 12.1 | Full Range -18.7 to 32.5 | percent change of terminal hair count |
| Percent Change in the Target Area Terminal Hair Count | Placebo Then Bimatoprost | Part 2: week 17 to week 34 | -5.1 | Full Range -22.7 to 8.2 | percent change of terminal hair count |
| Percent Change in the Target Area Terminal Hair Count | Bimatoprost Then Placebo | Part 2: week 17 to week 34 | -8.3 | Full Range -25.0 to 14.1 | percent change of terminal hair count |
| Percent Change in the Target Area Vellus Hair Count | Placebo Then Bimatoprost | Part 1: Baseline to week 17; | -2.6 | Full Range -16.7 to 17.6 | Percent change of vellus hair count |
| Percent Change in the Target Area Vellus Hair Count | Bimatoprost Then Placebo | Part 1: Baseline to week 17; | 78.1 | Full Range -45.9 to 406.0 | Percent change of vellus hair count |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo Then Bimatoprost | 3 | |
| Overall Study | STARTED | Bimatoprost Then Placebo | 6 | |
| Overall Study | COMPLETED | Placebo Then Bimatoprost | 3 | |
| Overall Study | COMPLETED | Bimatoprost Then Placebo | 6 | |
| Overall Study | NOT COMPLETED | Placebo Then Bimatoprost | 0 | |
| Overall Study | NOT COMPLETED | Bimatoprost Then Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo Then Bimatoprost | ||
| Total, all-cause mortality | Bimatoprost Then Placebo | ||
| Total, other adverse events | Placebo Then Bimatoprost | 0 | 3 |
| Total, other adverse events | Bimatoprost Then Placebo | 0 | 9 |
| Total, serious adverse events | Placebo Then Bimatoprost | 0 | 3 |
| Total, serious adverse events | Bimatoprost Then Placebo | 0 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Placebo Then Bimatoprost vs Bimatoprost Then Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02170662
GET https://conductscience.org/api/trials/v1/NCT02170662/registered